跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

06734

Supelco

泰莫西芬

certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

别名:

(Z)-1-(对二甲基氨基乙氧基苯基)-1,2-二苯基-1-丁烯, (Z)-2-[4-(1,2-二苯基-1-丁烯)苯氧基]-N,N-二甲基乙胺

登录查看公司和协议定价
所有图片(1)

About This Item

线性分子式:
C6H5C(C2H5)=C(C6H5)C6H4OCH2CH2N(CH3)2
CAS号:
10540-29-1
分子量:
371.51
EC號碼:
234-118-0
MDL號碼:
MFCD00010454
分類程式碼代碼:
41116107
PubChem物質ID:
329748268
NACRES:
NA.24

等級

certified reference material
TraceCERT®

品質等級

300

產品線

TraceCERT®

儲存期限

limited shelf life, expiry date on the label

製造商／商標名

Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

儲存條件

under inert gas (Argon)

技術

gas chromatography (GC): suitable

mp

97-98 °C (lit.)

形式

neat

儲存溫度

2-8°C

SMILES 字串

CC\C(c1ccccc1)=C(/c2ccccc2)c3ccc(OCCN(C)C)cc3

InChI

1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-

InChI 密鑰

NKANXQFJJICGDU-QPLCGJKRSA-N

基因資訊

human ... ESR1(2099)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般說明

该认证标准物质（CRM）根据ISO/IEC 17025和ISO 17034生产和认证。 该CRM可追溯来自NMI的原始材料，如NIST或NMIJ。
NMR定量信息已包括在认证内容中。证书上已给出不确定性和失效日期。
证书下载网址：http://www.sigma-aldrich.com

生化／生理作用

乳腺中的雌激素拮抗剂。阻止乳腺肿瘤细胞中的雌二醇刺激的 VEGF 的产生。蛋白激酶 C 抑制剂。
蛋白激酶 C 抑制剂。诱发人类恶性神经胶质瘤细胞系的细胞凋亡。他莫昔芬及其代谢产物 4-羟基他莫昔芬是选择性雌激素反应调节剂 (SERM)，在乳腺中用作雌激素拮抗剂。阻止乳腺肿瘤细胞中雌二醇刺激的 VEGF 的产生。

法律資訊

TraceCERT is a registered trademark of Merck KGaA, Darmstadt, Germany

象形圖

Health hazardEnvironment
GHS08,GHS09

訊號詞

Danger

危險聲明

H350,H360,H410

危險分類

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1A - Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.
Fisher B, et al.
Journal of the National Cancer Institute, 86(7), 527-537 (1994)
The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.
Shiau A K, et al.
Cell, 95(7), 927-937 (1998)
Usha Sundralingam et al.
Pharmaceutics, 12(9) (2020-08-29)
Oral tamoxifen used in the prevention and treatment of ductal carcinoma in situ (DCIS) (estrogen-positive) patients has limited acceptance, due to its adverse side effects. The efficacy of tamoxifen is related to its major metabolite, 4-hydroxytamoxifen. Local transdermal therapy of
Hang Yu Wang et al.
Journal of cellular physiology, 235(3), 2722-2737 (2019-09-12)
Liver fibrosis (LF) is the result of a vicious cycle between inflammation-induced chronic hepatocyte injury and persistent activation of hepatic stellate cells (HSCs). Mesenchymal stem cell (MSC)-based therapy may represent a potential remedy for treatment of LF. However, the fate
Ke Li et al.
Nature communications, 11(1), 6316-6316 (2020-12-11)
The transcription factor MYC is deregulated in almost all human cancers, especially in aggressive lymphomas, through chromosomal translocation, amplification, and transcription hyperactivation. Here, we report that high expression of tribbles homologue 3 (TRIB3) positively correlates with elevated MYC expression in
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门